THE CHALLENGE
Chronic subdural hematoma represents a significant unmet need in the neurosurgical and healthcare market, where current treatment pathways are both clinically and economically inefficient. Hospitals and providers rely heavily on surgical evacuation procedures that do not address the underlying inflammatory and angiogenic drivers of the disease, leading to recurrence rates as high as 26 percent and repeated hospital readmissions that increase cost burden and resource utilization. From a therapeutic development perspective, existing pharmacological options such as corticosteroids face major limitations due to poor site-specific bioavailability and dose dependent systemic toxicity, reducing their commercial viability and patient safety profile. This creates a clear gap for scalable, targeted solutions capable of locally modulating the pathological microenvironment, stabilizing fragile neovasculature, and interrupting disease progression. The lack of such localized and effective interventions not only impacts patient outcomes but also represents a substantial opportunity for innovation in drug delivery systems and minimally invasive therapeutics within a growing aging population.
OUR SOLUTION
A novel intracranial drug delivery platform addresses this gap by combining a scalable biomaterials approach with targeted therapeutic delivery to improve both clinical outcomes and healthcare efficiency. The system uses a biocompatible crosslinked gelatin-based hydrogel matrix to safely deliver a dual drug payload of minocycline and dexamethasone directly at the surgical site, enabling localized and sustained release for up to two months. By leveraging controlled release mechanisms such as electrostatic interactions and enzymatic degradation, the technology directly targets inflammation and abnormal blood vessel growth that drive recurrence, while avoiding systemic toxicity. Its mechanically durable and suturable design allows seamless integration into existing surgical workflows, reducing the likelihood of repeat procedures and associated costs. From a commercial perspective, this platform offers a differentiated, minimally invasive adjunct therapy with strong potential to lower hospital readmissions, improve patient recovery, and create a new category of localized neurotherapeutic solutions in a growing neurosurgical market.
Figure: Example gelatin hydrogel sheet rolled and sutured on end. White bar equals 1 cm.
Advantages:
Potential Application: